A Phase 3 Open-Label Randomized Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
Brief description of study
This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD9008 versus platinum-based doublet chemotherapy in participants with locally advanced or metastatic NSCLC with EGFR Exon20ins mutation, who are newly diagnosed or have not received prior systemic therapy in advanced stage.
Clinical Study Identifier: s22-01383
ClinicalTrials.gov Identifier: NCT05668988
Principal Investigator:
Elaine Shum.
Other Investigators:
Vamsidhar Velcheti,
Joshua K Sabari,
Samantha VanMaanen,
Elka R Travis,
Salman Rafi Punekar,
Jessica Wang,
Carol M Lee,
Laura Palazzolo,
James Newman,
Gabrielle Fridman,
Danny Perlaza,
Marissa Rybstein,
David Mendoza,
Natalia Cherkassky,
Jonathan B Kahn,
Jeffrey G Schneider,
Sally Lau,
Nitish Mehta,
Kirby Rodriguez,
Melissa L Martinez.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.